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Abstract Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of B lymphocytes. T cell
abnormalities are a common feature of CLL and contribute to impaired immune function in these patients. T cells are
ineffective in eliminating the leukemic clone and may actually promote tumor growth and survival. Previous work from
our laboratory documented elevated circulating levels of IL-17A-producing Th17 cells in CLL patients as compared to
healthy age-matched control subjects. These high circulating Th17 levels associated with better prognostic markers and
significantly longer overall survival, even among patients whose clones used unmutated IGHVs (U-CLL). Recent studies
suggest that Th17 cells are heterogeneous, expressing different profiles of cytokines, and that different subsets of Th17s
mediate different biological functions. In the present study, we found significantly higher levels of IL-17F-expressing
CD4? T cells in CLL versus healthy peripheral blood mononuclear cells following in vitro stimulation in the presence of
Th17-promoting cytokines. Furthermore, the differentiation of IL-17F-expressing Th17 cells was significantly enhanced
when purified CD4? T cells from CLL patients were cultured in the presence of autologous CLL B cells. Lastly, single-cell
network profiling revealed that IL-17F triggers NFjB phosphorylation in T and B cells from patients with CLL, but not
age-matched healthy controls. Taken together, our data suggest that the phenotype of Th17 cells in CLL patients is distinct
from healthy individuals, expressing higher levels of IL-17F, and that B and T cells from CLL patients are particularly
responsive to IL-17F, as compared to healthy age-matched control individuals.
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Abbreviations
BCR B cell antigen receptor





MFI Mean fluorescence intensity
mAb Monoclonal antibody
NFkB Nuclear factor kappa-light-chain-enhancer of
activated B cells
NHS Normal human serum
PBMCs Peripheral blood mononuclear cells
SCNP Single-cell network profiling
TTFT Time-to-first treatment
TGF-b1 Transforming growth factor b
Introduction
Chronic lymphocytic leukemia (CLL), the most common
adult leukemia in the USA, is characterized by the pro-
gressive accumulation of CD5? B lymphocytes [1, 2].
Growth and survival of the leukemic B cell clone are reg-
ulated by microenvironmental elements present within the
bone marrow and secondary lymphoid tissues [3]. CLL cells
receive critical antigen-triggered signals through the B cell
receptor (BCR) as well as regulatory input from a range of
accessory cells. These include T cells, stromal cells,
endothelial cells, follicular dendritic cells, and macrophages
that interact directly with leukemic B cells via a complex set
of adhesion molecules and cytokines [3]. Within lymphoid
tissues, T cells, mainly activated CD4? cells, reside in
proliferation centers and influence CLL growth and sur-
vival, presumably via CD40L–CD40 interactions [4]. In
addition to surface interactions, T cells secrete an array of
soluble factors that contribute to CLL cell survival and
proliferation, including IL-4, IL-2, TNFa, and IFN. The
requirement for T cells in CLL growth and survival is
supported by data from a xenograft model of CLL where
engraftment and proliferation of primary leukemic B cells
are dependent upon the presence of activated T cells [5].
T cell dysregulation is a common feature of CLL and is
thought to contribute to increased susceptibility to bacterial
and opportunistic infections in this population [6, 7]. In
CLL, leukemic B cells and/or the leukemic microenviron-
ment have been reported to trigger multiple T cell defects
including impaired formation of an immunologic synapse,
altered expression of co-stimulatory molecules, and
impaired cytotoxic killing of autologous tumors [8–10]. The
dysregulating influence of CLL cells themselves and the
CLL microenvironment on the T cell compartment is sup-
ported by studies showing a genetic signature for in vitro-
stimulated CD4? cells from patients with CLL consistent
with downregulation of T cell receptor signaling cascades
and reduced cytokine secretion [11]. The balance of T cell
subsets is also skewed in the context of CLL [7, 12–14].
Levels of regulatory T cells (Tregs), which are known to
suppress host antitumor immune responses, have been
reported to correlate with aggressive disease and time-to-
first treatment (TTFT) in patients with CLL [15–17]. In
addition, we and others have demonstrated that Th17 cells,
a subset of T cells with inflammatory properties, are ele-
vated in CLL and correlate with better outcome [16, 18].
Th17 cells are generated from naı¨ve T cells when they are
activated in the presence of a select set of cytokine signals that
include IL-1b, IL-6, IL-21, IL-23, and TGFb [38]. The early
observation of genetic mutations in STAT3 in patients with
hyperimmunoglobulinemia E (Job’s) syndrome [19] sug-
gested a role for this transcription factor in the differentiation
of Th17 cells. A large body ofwork now supports STAT3 as a
driving force in T cell differentiation into Th17, inducing the
transcription of IL-17A and the Th17-specific transcription
factor, retinoic acid receptor-related orphan nuclear receptor
(RORct). IL-6 and IL-21, two cytokines known to induce the
differentiation of naı¨ve CD4? T cells into Th17 cells, activate
the JAK/STAT pathway, suggesting that STAT3 activation
may be a commonmechanism through which these cytokines
regulate Th17 differentiation [20]. Further supporting a cen-
tral role for STAT3 in Th17 differentiation is the observation
that Th17 differentiation is prevented in CD4? T cells trans-
fected with STAT3 siRNA [20].
Th17 cells have been documented in several human
cancers including CLL and found to play pro- and antitu-
mor roles depending on the tumor [21–25]. While the
specific elements within the CLL microenvironment that
promote Th17 generation are currently unknown, we have
shown that two cytokines critical for Th17 differentiation
in healthy individuals, IL-1b and IL-6, are elevated in a
subset of CLL patients and belong to a cluster of cytokines
whose presence correlates with longer TTFT and longer
overall survival in this disease [26]. This finding, taken
together with our observation that Th17 levels are higher in
CLL patients with better prognosis, suggests that Th17
cells and cytokines that promote the development of Th17s
favor superior outcome in CLL.
However, the extent that IL-17A itself, or another one or
more of the cytokines released by Th17 cells (e.g., IL-17F),
exerts antitumor activity in this disease is not known. IL-
17A and IL-17F have many overlapping biological activi-
ties [27], but recent studies indicate that the two can
mediate discrete functions as well [28–30]. Both IL-17A
and IL-17F bind to the same heterodimeric receptors, IL-
17RA and IL-17RC, but with different affinities, which
may explain in part the overlapping and divergent activities
of these structurally very similar proteins [31]. In addition
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to differences in their bioactivity profiles, IL-17A and IL-
17F can be differentially regulated at the cellular and tissue
level, creating another layer of complexity. To date, Th17
cells in CLL patients have only been characterized with
respect to their expression of IL-17A; whether they express
and/or are responsive to IL-17F is not known.
Here, we report that levels of IL-17F produced by
cytokine activated Th17 cells derived from CLL patients
are significantly higher compared to healthy controls.
Furthermore, both leukemic B cells and CLL T cells are
responsive to IL-17F-mediated signaling, specifically
activating NFkB, whereas B and T cells from age-matched
healthy controls are not. Taken together, our data suggest
that in tissue microenvironments sustaining the activation
and division of leukemic B cells, the functional program of
Th17s in CLL might be distinct from that seen in healthy
subjects, favoring IL-17F production.
Materials and methods
Study population
Seventy-four CLL patients identified according to the
International Workshop on CLL diagnostic criteria [32] and
28 age-matched healthy volunteers participated in these
studies. Supplementary Table 1 reports clinical and labo-
ratory characteristics of patients and healthy age-matched
control subjects and indicates which studies were performed
with cells or serum from each CLL patient and healthy
subject. All CLL patients were untreated. All procedures in
this study (IRB# 08-202A) were in accordance with the
ethical standards of The North Shore—Long Island Jewish
Health System Office of the Institutional Review Board, and
informed consent was obtained from all study subjects.
Blood collection and processing
Peripheral blood mononuclear cells (PBMCs) from CLL
patients and healthy subjects were isolated from whole
blood by density gradient centrifugation using Ficoll-Paque
(GE Healthcare, Piscataway, NJ) and were frozen in fetal
calf serum plus 10 % dimethylsulfoxide (DMSO) in liquid
N2 (Sigma-Aldrich, St Louis, MO) for analysis at a later
point. For ex vivo (baseline/pre-stimulation) flow cyto-
metric analyses of Il-17F and IL-17A, frozen cells were
thawed and stained for surface phenotyping markers and
intracellular IL-17F and IL-17A as described.
Long-term cell culture
Frozen PBMCs from CLL and healthy subjects were
thawed and cultured for 7 days in 24-well plates pre-coated
for 2 h with 1 lg/ml anti-CD3 mAb (eBioscience Inc., San
Diego, CA) at a cell density of 1 9 106 cells per ml in
RPMI1640 medium supplemented with 10 % NHS (normal
human serum), 1 lg/ml anti-CD28 mAb (Beckman Coul-
ter, Indianapolis, IN), and a Th17-promoting cytokine
cocktail containing recombinant human IL-1b, IL-6, and
IL-23 (R&D Systems, Minneapolis, MN; 10 ng/ml final
concentration for all). At day 7, non-adherent cells were
collected, washed, and stained for surface markers and
intracellular IL-17F and IL-17A. For T ± CLL B cell co-
culture studies, frozen PBMCs from CLL patients (n = 3)
were thawed, and a portion of cells from each patient was
used for the isolation of CLL B cells using a B-CLL Cell
Negative Isolation Kit (Miltenyi Biotec Inc., San Diego,
CA). The remaining cells from each patient were used for
the isolation of CD4? T cells using a CD4? Cell Positive
Isolation Kit (Miltenyi Biotec Inc.). Cell purifications were
performed according to manufacturer’s protocols. Purified
CD4? T cells (1 9 105 cells/ml) were cultured for 7 days
on anti-CD3/CD28-coated 96-well microplates alone or
together with purified autologous CLL B cells at a B:T
ratio of 10:1. Various combinations of Th17-promoting
cytokines (10 ng/ml) were added to wells as indicated.
Each condition was set up in triplicate. At day 7, super-
natants were collected and analyzed for IL-17F and IL-17A
by ELISA.
Flow cytometric analysis of IL-17A and IL-17F in
PBMCs ex vivo and after 7-day stimulation with
anti-CD3/C28 mAbs
For detection of intracellular IL-17A and IL-17F, freshly
thawed PBMC suspensions from CLL patients and healthy
subjects were stimulated for 5 h with 10 ng/ml phorbol 12-
myristate 13-acetate (PMA) and 250 ng/ml ionomycin in
the presence of monensin (BD Biosciences, San Jose, CA).
Stimulated cells were centrifuged at 1200 g for 7 min at
10 C, washed, and then surface stained by incubating cells
(1–2 9 106/ml) for 30 min at room temperature in the dark
with antihuman mAbs: anti-CD3-APC-H7, anti-CD4-APC,
anti-CD8-PerCP (all BD Biosciences), and anti-CD161-
PerCPCy 5.5 (Biolegend, San Diego, CA). Cells were
subsequently fixed and permeabilized using Cell Fixation/
Permeabilization Kit (BD Biosciences) and stained intra-
cellularly with antihuman IL-17F PE (eBioscience Inc.) or
IL-17A AlexaFluor 488 (eBioscience Inc.) according to
manufacturer’s instructions. Samples were acquired on an
LSR II (BD Biosciences) and analyzed using FlowJo
software (version 8.8.6). IL-17F- and IL-17A-expressing
CD4? T cells in CLL and healthy PBMC cultures activated
for 7 days in vitro under Th17 polarizing conditions were
similarly analyzed.
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ELISA analyses
IL-17F and IL-17A levels were determined in supernatant
fluids using commercially available DuoSet ELISA kits
(R&D Systems) according to manufacturer’s directions.
IL-23 levels in stored, frozen serum samples from CLL
patients (N = 57) and age-matched normal healthy
(N = 15) control subjects were determined using a com-
mercially available ELISA kit (R&D Systems) according
to manufacturer’s directions. All analyses were carried out
in duplicate. Statistical significance was examined by the
Mann–Whitney test (comparison of ex vivo and in vitro-
stimulated IL-17F levels in CLL and healthy PBMCs) or
two-way ANOVA (T ± CLL B cell co-culture studies).
Single-cell network profiling (SCNP) assay
SCNP, a multiparametric, single-cell flow cytometry anal-
ysis approach [33–35], was used to analyze the respon-
siveness of cryopreserved PBMCs from 13 CLL patients and
four healthy donors. Responsiveness of CLL and healthy B
and T cells to modulators including IL-17F, IL-17A, IL-6,
and IL-1b (R&D Systems) was quantified simultaneously
across multiple nodes (a node being an extracellular mod-
ulator combined with a specific intracellular readout, e.g.,
IL-17 ? pNFkBp105) in multiple immune cell subsets
including CD4?CD3? and CD4-CD3? (CD8) T cells as
well as CD19? B cells in healthy donors and CD19?CD5?
cells in CLL patient samples. SCNP is performed without
cell subset isolation, thereby allowing the examination of
functional cell signaling in individual cells and cross-talk
among different cells [33]. Cells were incubated in 96-well
plates with 100,000 cells per well and either unmodulated
(capturing basal signaling) or modulated with the above-
mentioned cytokines. Cells were fixed, permeabilized and
incubated with a cocktail of fluorochrome-conjugated anti-
bodies that recognize extracellular lineage markers and
intracellular epitopes. Evoked intracellular signaling in the
NFkB (p-NFkBp105), PI3K (p-AKT), MAPK (p-ERK), and
STAT (p-STAT1, p-STAT3, pSTAT5) pathways was
quantified at 5 min post-stimulation.
Statistical analyses
Group comparisons were carried out using the Mann–
Whitney test, Wilcoxon matched-pairs signed rank test,
unpaired two-sided Student’s t test, or two-way analysis of
variance (ANOVA), as appropriate. Pairwise comparisons
were carried out using a Bonferroni-type adjustment
(p\ 0.01). All statistical analyses were performed by
GraphPad Prism version 6.0 for Windows (GraphPad
Software, San Diego, CA). In all cases, p\ 0.05 was
accepted as significant.
Results
Ex vivo levels of Th17F cells are higher in CLL
PBMC as compared to healthy controls
Th17 cells are classically defined by expression of IL-17A,
but they can produce IL-17F as well. While IL-17A and IL-
17F are highly homologous and exert some overlapping
biological activities, they are distinct molecules with a
number of discrete functions. We compared the expression
of IL-17F in circulating CD4? T cells from CLL patients
(n = 21) and age-matched healthy controls (n = 9) at
baseline by intracellular flow cytometry using the strategy
outlined in Fig. 1a. The percentage of IL-17F-expressing
CD4? T cells trended higher in CLL patients as compared
to healthy age-matched individuals, but the difference did
not reach statistical significance (p = 0.099) (Fig. 1b).
IL-23 levels are significantly higher in CLL than
control sera from normal donors
Our finding that ex vivo levels of Th17F cells trended
higher in CLL PBMCs as compared to healthy controls
suggests the presence within the CLL microenvironment of
elements (e.g., cytokines) that favor Th17 cell differentia-
tion. Cytokines known to induce the differentiation and/or
expansion of Th17s include IL-1b, IL-6, and IL-23, among
others [36–38]. Our previous work revealed that circulating
levels of IL-1b and IL-6 are elevated in a subset of CLL
patients and that these two cytokines belong to a cluster of
cytokines whose presence correlates with longer TTFT and
overall survival in the CLL patient population [26]. To
determine whether levels of IL-23 were also elevated in the
context of CLL, we measured the levels of this cytokine in
serum samples collected from CLL patients (N = 57) and
age-matched healthy donors (N = 15) by sandwich ELISA.
Serum levels of IL-23 were significantly elevated in CLL
patients as compared with healthy controls (p = 0.0001)
(Fig. 2). Considerable heterogeneity was observed in the
serum IL-23 levels in different CLL patients. Whether
serum IL-23 levels correlate with specific prognostic
markers (e.g., mutational status, CD38 expression) remains
to be determined.
CLL PBMCs exhibit higher IL-17F-expressing Th17
cells after 7 days in vitro under activating conditions
than PBMCs from healthy donors
We next analyzed the percentages of CD4? IL-17F-ex-
pressing cells in CLL (n = 12) and healthy (n = 5)
PBMCs activated in vitro by TCR cross-linking. When
PBMCs were activated with anti-CD3/CD28 for 7 days in
culture in the presence of a cocktail of Th17-promoting























Fig. 1 Percentage of IL-17F-expressing Th17 cells in the blood of
CLL patients versus healthy controls. a Flow cytometry strategy to
quantify IL-17F-expressing CD4? T cells (‘‘Th17F’’). PBMCs from a
single age-matched healthy control subject were stained for surface
markers and intracellular IL-17F and analyzed by flow cytometry. Plots
illustrate gating of the terminally selected ‘‘Th17F’’ (CD3?CD4?IL-
17F?) population (lower left plot). Back-gating shows that the ‘‘Th17F’’
population (black highlighted cells in all plots) selected for analysis is
comprised of singlet lymphocytes (upper left and middle plots) that are
CD3? (upper right plot) and CD4? (lower right plot). b Frozen aliquots
of PBMCs from CLL patients (n = 21) and healthy age-matched
individuals (n = 9) were thawed and stained for surface markers and
intracellular IL-17F (or IL-17A) and analyzed by flow cytometry.
Statistical significance was examined by the Mann–Whitney test
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cytokines (Fig. 3a), the percentages of CD4? T cells
expressing IL-17F were significantly higher for CLL as
compared to control PBMCs (p = 0.0136). When PBMCs
were activated for 7 days in the absence of exogenously
added Th17-promoting cytokines, no significant difference
between baseline and day 7 percentages was observed for
either CLL (p = 0.5438) or healthy (p = 0.4258) (data not
shown). In a subsequent analysis, we compared the per-
centage of IL-17F-expressing CD4? T cells at baseline and
after activation in the presence of Th17-promoting
cytokines for each patient (Fig. 3b, left panel) and healthy
donor (Fig. 3b, right panel). In all CLL patients with the
exception of one, the percentage of IL-17F-expressing
CD4? T cells was higher after in vitro activation in the
presence of the Th17-promoting cytokine cocktail, with the
positive change between baseline and day 7 being statis-
tically different (p = 0.0010). For age-matched healthy
subjects, the percentage of CD4? T cells expressing IL-17F
was not statistically different between baseline and day 7
(p = 0.1250). A similar comparison was performed for IL-
17A, and the percentage of IL-17A-expressing CD4? T
cells in CLL PBMCs (n = 12) at baseline was not statis-
tically different from the percentage observed after cells
were activated with anti-CD3/CD28 for 7 days in either the
presence or absence of Th17-promoting cytokines
(p = 0.8125 and 0.9548, respectively; data not shown).
CLL B cells enhance the generation of IL-17F-
producing Th17s in vitro
Since the previous set of experiments was performed with
whole PBMC cultures, the higher percentages of IL-17F-
expressing CD4? T cells observed in CLL PBMCs could
reflect an inherent difference in the CLL T cells themselves
or a modulatory effect mediated by autologous CLL B cells
or another immune cell present in the CLL PBMC popu-
lation. To begin to directly assess whether CLL B cells
promote T cell differentiation to IL-17F-producing Th17s,
purified CD4? T cells from three independent CLL patients
were cultured alone or together with autologous CLL B
cells for 7 days in the presence (or absence) of various
combinations of Th17-polarizing cytokines (IL-6, IL-1b,



















































Fig. 3 CLL PBMCs exhibit higher IL-17F-expressing Th17 cells after
7 days in vitro activation under Th17-polarizing conditions than
PBMCs from healthy donors. a PBMCs from CLL patients (n = 12)
and healthy age-matched control subjects (n = 5) were stimulated
in vitro with anti-CD3/CD28 mAbs for 7 days in the presence of a
Th17-promoting cocktail (IL1 ? IL23). At day 7, cells were collected,
stained for surface markers and intracellular IL-17F (or IL-17A) and
analyzed by flow cytometry. Statistical significance was examined by
the Mann–Whitney test. b Comparison of IL-17F-expressing CD4? T
cell percentages for individual CLL patients (n = 12; left panel) and
age-matched healthy subjects (n = 5; right panel) pre- and post-
stimulation by TCR cross-linking for 7 days in the presence of a Th17-
promoting cocktail (IL1 ? IL23). Statistical significance was examined









Fig. 2 IL-23 levels are significantly higher in CLL versus control
sera. Serum samples from CLL patients (N = 57) and age-matched
normal healthy control subjects (N = 15) were analyzed for IL-23 by
sandwich ELISA. Serum levels of IL-23 were significantly higher in
CLL patients (p = 0.0001) compared with age-matched control
subjects. Statistical significance was examined by the Mann–Whitney
test
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the supernatant fluid at day 7 were higher when CD4? T
cells were co-cultured with CLL B cells as compared to
when CD4? T cells were cultured alone (Fig. 4). A two-
way ANOVA indicated that the enhancement observed
upon addition of CLL B cells was significant (p = 0.0242).
Post hoc analyses employing Bonferroni correction
revealed that the enhancing effect of CLL B cells on CD4?
T cell IL-17F production was significant only in cultures
differentiated in the presence of IL-6 ? IL-1 ? IL-23
(p = 0.0017). A significant difference in IL-17F levels was
also observed in cultures treated with different combina-
tions of Th17-inducing cytokines (p = 0.0079). Lastly, a
significant interaction effect (p = 0.0287) was observed
between the addition of CLL B cells and the particular
Th17-promoting cytokine(s) added indicating that the
stimulatory effect of CLL B cells on IL-17F production by
CD4? T cells is dependent upon the specific cytokine
cocktail used to trigger Th17 differentiation.
IL-17F triggers increased NFkB signaling in CLL B
cells
To begin to address the functional implications of the
presence of elevated levels of IL-17F in CLL, we analyzed
the responsiveness of CLL (n = 13) and age-matched
healthy PBMCs (n = 4) to IL-17F and IL-17A using a
SCNP approach. A modest increase in activation of the
canonical pNFkBp105 pathway was observed in CLL B
cells but not healthy donor B cells following IL-17F
modulation (Fig. 5), the difference between the two donor
populations being significant (p\ 0.05) as measured by
the two-sided Student’s t test. A weak increase in
pNFkBp105 pathway signaling above baseline was
observed in response to IL-17A for CLL B cells; however,
the difference between CLL and healthy donor B cell
signaling was not significant. These data highlight the
activation of distinct IL-17 signaling pathways in CLL. IL-
17-modulated signaling appeared to be specific to the
NFkB pathway in this study, as there was no activation of
pAkt or pERK after either IL-17F or IL-17A modulation
(data not shown).
Although significant differences in IL-17F-modulated
signaling between CLL and healthy B cells were identified,
analysis of receptor expression levels in a subset of donors
suggested that IL-17RA and IL-17RC receptor expressions
were comparable between CLL and healthy B cells (data
not shown). Thus, this analysis of modulated signaling
indicates that the identified functional alterations were not
Fig. 5 IL-17F triggers NFjB signaling in CLL, but not in healthy B
cells. a CLL and healthy PBMCs were stimulated with IL-17F (20 ng/
ml) or IL-17A (20 ng/ml) for 5 min. Phosphorylation of NFjB p105
was examined on CD19? B cells by calculating the fold change in
mean fluorescence intensity (MFI) for treated cells as compared to
untreated cells for each donor sample. Each circular dot represents an
individual CLL patient or healthy donor in which there were at least
100 gated CD19? cells. A similar analysis was performed for ERK
(T202/Y204) and Akt (S473) (data not shown). Statistical significance
between CLL and healthy was examined by unpaired two-sided



































Fig. 4 Addition of autologous CLL B cells to purified CD4? T cells
enhances production of IL-17F. Purified CD4? T cells from a subset
of CLL patients (n = 3) were cultured for 7 days on anti-CD3/CD28-
coated plates alone or together with purified autologous CLL B cells
at a B:T ratio of 10:1 and various Th17-promoting cytokine
combinations (IL-6, IL-1b, IL-1b ? IL-6, IL-6 ? IL-1b ? IL-23;
all cytokines at 10 ng/ml). At day 7, supernatants were collected and
analyzed for IL-17F by ELISA. Data are presented as fold change
relative to CD4? T cell only cultures (no cytokine additions).
Comparisons were made using two-way ANOVA followed by
Bonferroni post hoc tests to compare effects of addition of CLL B
cells and various cytokine treatments. (***p = 0.001)
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revealed by surface phenotyping and were not due to dif-
ferences in levels of expression of receptor molecules for
the IL-17 ligands, but instead resulted from altered func-
tional signaling capacity in the B-CLL cells.
IL-17F triggers increased NFkB signaling in CLL T
cells
We also examined signaling cascades triggered by IL-17F
and IL-17A in T cells from the same cohort of 13 CLL
patients and four healthy control subjects. IL-17F triggered
a modest increase in activation of the canonical
pNFkBp105 pathway in CLL donor CD4-CD3?T (CD8)
cells and CD4?CD3? T cells (Fig. 6) but no activation of
signaling in healthy donor T cells. In contrast to IL-17F,
IL-17A induced weak to no activation of the canonical
pNFkBp105 pathway in either population of T cells
(CD4-CD3? and CD4?CD3?) in CLL and healthy donor
samples. These data indicate potentially different functions
for the two cytokines in CLL and a difference in IL-17F
responsiveness between CLL and healthy donor T cells. As
in CLL B cells, no IL-17F ? pAKT or pErk signaling was
observed.
Dysregulation of signaling by Th17-inducing factors
may enhance Th17F cell differentiation
Because the differentiation and expansion of Th17 cells are
dependent upon signals supplied by the cytokines IL-6 and
IL-1b, among others [36–38], we next analyzed signaling
downstream of IL-6 (measured via p-STAT1/3/4) and IL-
1b (measured via pNFkBp105) in CD4?CD3? and
CD4-CD3? T cells from CLL patients and healthy con-
trols. For both CLL and healthy T cells, treatment with IL-
6 induced greater phosphorylation of STAT3 and STAT1
in CD4?CD3? as compared to CD4-CD3? (CD8) T cells
(Fig. 7a). Of note, STAT1 phosphorylation was signifi-
cantly higher in healthy versus CLL CD4?CD3? T cells
(p\ 0.005), while the levels of STAT3 phosphorylation
were overall higher in healthy but were not significantly
different. Further, the ratios of IL-6-induced pSTAT3 to
pSTAT1 in CD4?CD3? T cells trended higher for CLL
than healthy, although the differences were not statistically
significant (Fig. 7b). By comparison the ratio of pSTAT3
to pSTAT4, while also higher in CLL than healthy, was
less marked. Upon IL-1b modulation, both CLL CD4?-
CD3? and CD4-CD3? T cells displayed greater phos-
phorylation of NFkBp105 than healthy (Fig. 7c).
Discussion
CLL is the most common adult leukemia in the USA, and
despite extensive clinical and basic research, the disease
remains incurable. It is clear that the cellular and cytokine
microenvironment surrounding leukemic B cells greatly
influences the growth and survival of the clone, providing
pro- and antitumor signals [3]. T cell dysregulation is a
common feature of CLL, characterized by impaired
immune synapse formation and altered T-subset balance
[6–8, 13]. The role of T cell subset balance in host anti-
tumor immune responses is complex and incompletely
understood, with specific subsets having variable and at
times opposite effects in the setting of different tumors. We
recently identified a previously unrecognized correlation
between the absolute number of circulating Th17s and
clinical outcome in CLL [18]. We further showed that the
Th17-promoting cytokines IL-6 and IL-1 are elevated in a
subset of CLL patients and are members of a cluster of
cytokines whose presence correlates with longer TTFT and
Fig. 6 IL-17F triggers NFjB signaling in CLL, but not in healthy
CD4-CD3? (CD8?) cells. a CLL and healthy PBMCs were
stimulated with IL-17F (20 ng/ml) or IL-17A (20 ng/ml) for 5 min.
Phosphorylation of NFjB p105 was examined on CD4?CD3? and
CD4-CD3? T cells by calculating the fold change in MFI for the cells
in the IL-17F modulated as compared to the unmodulated (basal
control) well for each donor sample. Each circular dot represents an
individual CLL patient or healthy donor in which there were at least
100 gated cells. A similar analysis was performed for ERK (T202/
Y204) and Akt (S473) (data not shown). Statistical significance
between CLL and healthy was examined by unpaired two-sided
Student’s t test (*p\ 0.05)
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longer overall survival in this disease [26]. These findings
suggested for the first time that Th17s and cytokines that
promote the development of Th17s favor better clinical
outcome.
The Th17/IL-17 axis can play pro- and antitumor roles
depending upon the type of malignancy studied [21–25].
The underlying basis for this apparent discrepancy may
reflect differences between the tumors themselves, but may
also reflect the pleiotropic nature of Th17 actions, some of
which promote (e.g., angiogenesis) and others inhibit (e.g.,
CTL activation) tumor growth. The wide range of Th17
actions is presumably a result of the fact that this T cell
subset produces multiple cytokines in addition to IL-17A,
including IL-17F, IL-22, IL-21, IL-10 IL-9, and CCL20,
each of which has a unique profile of biological functions.
In the current study, we analyzed the expression of IL-17F
in CD4? T cells from CLL patients and age-matched
healthy donors. We report that both circulating (Fig. 1b)
and in vitro differentiated (Fig. 3a, b) Th17 cells express
higher levels of IL-17F than similarly isolated or in vitro
differentiated Th17 cells from healthy age-matched indi-
viduals, although the difference was statistically significant
only in the case of Th17 cells activated for 7 days in vitro
in the presence of Th17-promoting cytokines. It is of
interest to note that circulating levels of IL-17F-expressing
CD4? T cells appear to fall into two discrete clusters, one
displaying a relatively high percentage of IL-17F-ex-
pressing CD4? T cells and the other displaying levels
comparable to, or even lower than, those observed for age-
matched healthy donors (Fig. 1b). Studies are currently
underway to determine whether these clusters correlate
with CLL prognostic markers (e.g., mutation status, CD38
expression) or clinical status (overall survival, TTFT).
IL-17F is highly homologous to IL-17A both struc-
turally and functionally, and the two cytokines bind to the
same receptor, albeit with different affinities [27], but there
is increasing evidence that the two have discrete functions
as well [27–30]. Therefore, it is of considerable interest
that although the levels of IL-17F-expressing CD4? T cells
are higher in CLL versus healthy PBMCs following in vitro
stimulation for 7 days in the presence of Th17-promoting
cytokines, the percent of IL-17A-expressing CD4? T cells
are not (data not shown). This suggests that the balance of
cytokines secreted by CLL Th17 cells differentiated within
the CLL cellular microenvironment (mimicked in our
PBMC cultures) may differ from that observed in Th17
cells differentiated within a ‘‘non-CLL’’ cellular microen-
vironment (IL-17F higher relative to IL-17A in Th17 cells
differentiated within CLL milieu). Since there are
Fig. 7 Dysregulation of signaling by Th17-inducing factors may
enhance Th17F cell differentiation. a, b CLL and healthy PBMCs
were stimulated with IL-6 (50 ng/ml) (a) or IL-1b (100 ng/ml) (c) for
5 min. Phosphorylation of STAT1, STAT3, STAT4, or NF-kBp105
was examined on CD4?CD3? and CD4-CD3? T cells, by calculating
the fold change in MFI for the cells in the modulated as compared to
the unmodulated (basal control) wells for each donor sample. b For
CD4?CD3? T cells, the ratio of IL-6-induced pSTAT3 to pSTAT1, as
well as the ratio of IL-6-induced pSTAT3 to pSTAT4, was calculated
for each donor sample. Each circular dot represents an individual
CLL patient or healthy donor in which there were at least 100 gated
CD4?CD3? or CD4-CD3? cells. Statistical significance was exam-
ined by unpaired Student’s t test (*p\ 0.05; **p\ 0.005)
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differences in receptor binding affinity, signaling, and
bioactivity profiles between IL-17F and IL-17A, the func-
tional program of Th17s in CLL tissue microenvironments
might be distinct from that seen in healthy subjects.
Th17 cells are generated from naı¨ve T cells when they
are activated in the presence of a select set of cytokines that
include IL-1b, IL-6, IL-21, IL-23, and TGFb. The mech-
anisms that regulate Th17 differentiation in the context of
CLL are unknown, although the Th17-inducing cytokines
IL-1b and IL-6 are elevated in a subset of CLL patients
with good prognosis [26] and presumably drive Th17 dif-
ferentiation in that population. Herein, we report that IL-
23, a cytokine critical for Th17 cell maintenance and
expansion, is also significantly elevated in serum from CLL
patients as a whole compared to age-matched healthy
controls (Fig. 2). This finding suggests a potential mecha-
nism that may contribute to the higher circulating levels of
CD4? T cells expressing IL-17F (this study) and IL-17A
[18] observed in CLL patients. It is interesting to note that
we observed considerable heterogeneity in serum IL-23
levels among CLL patients. It remains to be determined
whether serum IL-23 levels correlate with specific prog-
nostic markers (e.g., mutation status, CD38 expression) or
clinical status (overall survival, TTFT). Under normal
conditions, the relative levels of p-STAT proteins within
lymphocytes are believed to control T cell differentiation,
with the ratio of p-STAT3:p-STAT1 being a critical ther-
mostat in the Th17 differentiation axis, a higher p-
STAT3:p-STAT1 favoring Th17 generation [39]. There-
fore, our finding that IL-6-stimulated CD4? T cells from
CLL patients displayed a higher ratio of p-STAT3, a pro-
Th17 factor, relative to p-STAT1, an inhibitory Th17 fac-
tor, than CD4 ? T cells from healthy subjects (Fig. 7),
raises the possibility that CD4? T cells from CLL patients,
or a subset of CLL patients, are ‘‘primed’’ to differentiate
along the Th17 lineage in response to activation signals.
A growing body of literature supports the existence of
multiple forms of Th17 cells expressing different profiles
of cytokines and mediating different biological functions.
The CLL-specific microenvironmental triggers that induce
the generation of a population of Th17 cells with unique
secretory properties (higher levels of IL-17F relative to
IL17A) are as yet unknown. Our finding that the coculture
of CLL B cells with autologous CD4? T cells leads to
higher percentages of IL-17F-expressing Th17 cells
(Fig. 4) suggests that the CLL B cell itself, in certain
contexts, has the capacity to trigger a signaling pathway(s)
in the T cell that drives Th17 differentiation or expansion.
Of potential relevance is a recent report demonstrating that
CD5 co-stimulation induces stable Th17 development
in vitro by promoting IL-23R expression and sustained
STAT3 activation [40]. In humans, there is no confirmed
ligand for CD5, but there is evidence that CD72, a C-type
lectin, may interact with CD5 or that CD5 may be homo-
philic, permitting binding of CD5 on the surface of adja-
cent cells [41]. Moreover, there is another, potentially
complementary role that CLL B cells might be playing.
Naı¨ve T cells do not express the IL-23R, which would
make them unresponsive to this critical Th17-inducing
cytokine signal [42]. CD5, which is highly expressed on
CLL, but not healthy B cells, has been reported to induce
IL-23R in naı¨ve cells. This suggests a second mechanism,
whereby the CLL B cell could enhance IL-17-expressing
Th17 generation in our coculture system—upregulation of
IL-23R on naı¨ve CD4? T cells via homotypic interactions
through CD5, and then supplying the IL-23. At this point,
the increased levels of IL-23 in the serum of CLL patients
(Fig. 2) have not been shown to derive directly from the
CLL B cell, although results from our coculture studies
could be interpreted as CLL B cells partially supplement-
ing the requirement for IL-23 in the Th17 cocktail (Fig. 4).
The extent that CLL B cells or another cell in the CLL
microenvironment selectively promotes IL-17F (or IL-
17A) production remains to be explored.
To begin to interrogate the signaling interplay of high
IL-17F-expressing Th17 cells with CLL cells and the
tumor microenvironment, we performed SCNP analyses in
which PBMC samples from CLL patients and healthy
donors were incubated in vitro with IL-17F and the evoked
signaling in pathways known to be triggered by IL-17F,
including NFjB (p105NFkB), PI3K (p-Akt), and MAPK
(p-ERK), was quantified. Surprisingly, we found that IL-
17F (but not IL-17A) stimulated NFjB activation in CLL
B cells but not B cells from healthy subjects (Fig. 5).
Leukemic B cells from CLL patients studied immediately
ex vivo often exhibit high levels of activated NFjB [43],
although this can differ among individual subjects [44]. For
those with elevated active NFjB, this finding suggests
either constitutive activation or ongoing stimulation of the
pathway in vivo. Multiple mechanisms, including BCR
engagement, have been reported to activate NFjB in the
context of CLL [45]. Our finding that IL-17F triggers
NFjB signaling in CLL B cells identifies another potential
mechanism within the CLL microenvironment that may
mediate NFjB activation. Furthermore, the fact that stim-
ulation of NFjB signaling was accomplished only by IL-
17F, not IL-17A and occurred only in CLL B cells and not
those from healthy donors is provocative, and the clinical
association of this interaction is under study. Finally, the
inability to detect a robust signaling event after IL-17A
exposure, as measured by signaling through NFjB, Akt, or
Erk activation, highlights the unique actions of IL-17F in
the disease.
In addition, our finding that IL-17F also triggers NFkB
activation in CD4-CD3? (CD8) cells, but not CD4?CD3?
T cells (Fig. 6), is particularly intriguing. The role of Th17s
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in antitumor immunity remains controversial, with some
studies demonstrating pro-tumor and other studies antitu-
mor effects. This has been presumed to reflect the at times
opposing functions of the cytokines produced by Th17
cells. IL-17A produced by Th17 cells promotes tumor
growth by inducing angiogenesis, while IL-21 produced by
Th17 cells mediates antitumor effects including induction
of apoptosis. Our finding that IL-17F, another cytokine
variably produced by Th17 cells, activates the NFkB sig-
naling cascade in CD8 T cells, which are known to play an
important antitumor role, suggests an additional, antitumor
mechanism—the recruitment and/or activation of antitu-
mor immune cells. In order to be able to evaluate the
clinical influence of Th17 cells in a particular clinical sit-
uation, it is necessary to evaluate the profile of cytokines
released by endogenous Th17 cells. One could envision
that in patients with the same disease, differences within
the microenvironment could modulate the types of
cytokines secreted by Th17 cells (and other T cell subsets),
thereby differentially influencing outcome.
In summary, our studies have demonstrated that the
levels of IL-17F-expressing CD4? T cells are significantly
higher in CLL versus healthy PBMCs following in vitro
stimulation in the presence of Th17-promoting cytokines
and that both leukemic B cells and CLL T cells are
responsive to IL-17F-mediated signaling, specifically
activating NFkB. Taken together, our data suggest that in
tissues where most activation and division occur, the
functional program of Th17s in CLL might be distinct from
that seen in healthy subjects, favoring IL-17F production
and responsiveness. It remains unclear at this point whether
the effects of IL-17F on cells in the leukemic microenvi-
ronment are capable of mediating tumor-promoting or
tumor-suppressing actions.
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